Last updated on June 2019

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC


Brief description of study

A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in advanced ALK-positive NSCLC patients who are treatment nave and to compare lorlatinib to crizotinib with respect to overall survival in the same population

Clinical Study Identifier: NCT03052608

Find a site near you

Start Over

Hopital Pierre Paul Riquet

Toulouse cedex 9, France
0.54miles
  Connect »

H pital Larrey

Toulouse cedex 9, France
0.54miles
  Connect »

lnstitut Claudius Regaud

Toulouse cedex 9, France
0.54miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.